Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
11(73%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
5
33%
Ph phase_1
2
13%
Ph phase_3
7
47%

Phase Distribution

2

Early Stage

5

Mid Stage

7

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
2(14.3%)
Phase 2Efficacy & side effects
5(35.7%)
Phase 3Large-scale testing
7(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

11

trials recruiting

Total Trials

15

all time

Status Distribution
Active(11)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Active, not recruiting6
Recruiting5
Completed2
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
11
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (14.3%)
Phase 25 (35.7%)
Phase 37 (50.0%)

Trials by Status

withdrawn17%
active_not_recruiting640%
recruiting533%
unknown17%
completed213%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT07421167Phase 2

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

Recruiting
NCT05653219Phase 3

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Active Not Recruiting
NCT05653349Phase 3

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

Active Not Recruiting
NCT07039422Phase 2

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

Recruiting
NCT05885555Phase 2

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

Active Not Recruiting
NCT07244289

Managed Access Programs for VAY736, Ianalumab

Unknown
NCT05648968Phase 3

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

Active Not Recruiting
NCT06133972Phase 3

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

Recruiting
NCT06711887Phase 3

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

Recruiting
NCT06470048Phase 2

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

Recruiting
NCT05624749Phase 3

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

Active Not Recruiting
NCT05639114Phase 3

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

Active Not Recruiting
NCT05124925Phase 2

Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.

Completed
NCT03574545Phase 1

Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis

Completed
NCT06411639Phase 1

Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases

Withdrawn

All 15 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
15